Follow RARE's trial news. Pro members can get an alert when Ultragenyx Pharmaceutical files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 55% from its Dec 4, 2025 high.
| Since its Dec 2021 high | Down 81% |
| Latest filing | 10-Q, Nov 4 |
After its last 4 reports it closed -2.3% on average, higher 2 of 4 times.
About 3 quarters
No shelf registration or at-the-market program on file in the last three years.
CFO Howard Horn sold 7,066 shares on Oct 15. 22 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
RARE is #171 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 171 |
Expected to report Tue Feb 9, after the close (in 91 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $173.0M, 8% more than a year ago; a loss of $1.16 a share, from $1.81.
“EVKEEZA® revenue in the third quarter 2026 was $24 million, driven by increased demand from new country launches and early access.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $105M | $112M | $95M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 4)
| Measure | Figure |
|---|---|
| Total revenue | $730M to $760M |
“The company continues to anticipate achieving full-year GAAP profitability in 2027 and going forward.”
From its results filing (SEC filing · Nov 3)
Sales grew 20% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 10% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +2.5% | +3.2% | -3.0% |
| Aug 4, 2026 | +10.3% | -3.4% | +4.5% |
| May 5, 2026 | +3.6% | +3.7% | +7.3% |
Sales grew every year from 2018 to 2025, to $673M. It lost money in each of the eight years.
RSI 49.9, MACD above signal, above its 50-day, below its 200-day. Not scored.
3 insiders sold $160K across 3 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: RARE is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
“With respect to Crysvita, although we are not aware of any other products currently in clinical development by a competitor for the treatment of XLH and TIO, it is possible that competitors may produce, develop, and commercialize therapeutics, or utilize other approaches such as gene therapy, to treat XLH and TIO.”
RARE scores -2 today, which Breakaway calls Poor. It is #171 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 55% from its Dec 4, 2025 high. Cash lasts about 3 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
RARE scores -2 today, which Breakaway calls Poor (below zero). That is #171 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RARE's -2.
3 insiders sold $160K across 3 filings in the last 6 months. No open-market buys on record. The newest is Howard Horn, Chief Financial Officer, who sold $108K on Oct 15. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.